Halozyme Therapeutics Inc (HALO) concluded trading on Wednesday at a closing price of $70.14, with 9.68 million shares of worth about $679.02 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 22.73% during that period and on May 07, 2025 the price saw a gain of about 18.12%. Currently the company’s common shares owned by public are about 123.17M shares, out of which, 122.23M shares are available for trading.
Stock saw a price change of 14.20% in past 5 days and over the past one month there was a price change of 18.18%. Year-to-date (YTD), HALO shares are showing a performance of 46.71% which increased to 75.75% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $40.87 but also hit the highest price of $66.00 during that period. The average intraday trading volume for Halozyme Therapeutics Inc shares is 1.48 million. The stock is currently trading 16.25% above its 20-day simple moving average (SMA20), while that difference is up 14.88% for SMA50 and it goes to 24.53% higher than SMA200.
Halozyme Therapeutics Inc (NASDAQ: HALO) currently have 123.17M outstanding shares and institutions hold larger chunk of about 99.64% of that.
The stock has a current market capitalization of $8.66B and its 3Y-monthly beta is at 1.26. PE ratio of stock for trailing 12 months is 18.61, while it has posted earnings per share of $3.77 in the same period. Its PEG reads 0.65 and has Quick Ratio of 7.30 while making debt-to-equity ratio of 3.13. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HALO, volatility over the week remained 5.07% while standing at 4.58% over the month.
Stock’s fiscal year EPS is expected to rise by 26.57% while it is estimated to increase by 33.81% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on October 07, 2024 offering an Equal weight rating for the stock and assigned a target price range of between $58 and $62 to it. Coverage by JP Morgan stated Halozyme Therapeutics Inc (HALO) stock as a Neutral in their note to investors on September 19, 2024, suggesting a price target of $57 for the stock. On June 07, 2024, Piper Sandler Downgrade their recommendations, while on February 29, 2024, TD Cowen Initiated their ratings for the stock with a price target of $54. Stock get a Buy rating from H.C. Wainwright on July 24, 2023.
